CA2129079C — Orally administrable cholesterol lowering agent
Assigned to Mitsubishi Chemical Corp · Expires 2006-01-17 · 20y expired
What this patent protects
There is provided an orally administrable cholesterol lowering agent which is obtained by coating with hydroxypropylmethylcellulose, plain tablets containing an anion exchange resin as an active component and containing 14-20% by weight of water and not more than 2% by weight of …
USPTO Abstract
There is provided an orally administrable cholesterol lowering agent which is obtained by coating with hydroxypropylmethylcellulose, plain tablets containing an anion exchange resin as an active component and containing 14-20% by weight of water and not more than 2% by weight of silicon dioxide based on the weight of the anion exchange resin. The orally administrable cholesterol lowering agent is obtained by coating the above mentioned tablets with an aqueous solution of 10-30 cSt of hydroxypropylmethylcellulose. In addition to being easy to swallow, the orally administrable cholesterol lowering agent of the present invention is superior in the compressing shapeability, stability in a humid environment, and fluidity.
Drugs covered by this patent
- Renvela (SEVELAMER CARBONATE) · Sanofi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.